VXRT
Price:
$0.6012
Market Cap:
$136.76M
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dyspla...[Read more]
Industry
Biotechnology
IPO Date
1981-12-11
Stock Exchange
NASDAQ
Ticker
VXRT
According to Vaxart, Inc.’s latest financial reports and current stock price. The company's current ROE is -110.46%. This represents a change of 284.03% compared to the average of -28.76% of the last 4 quarters.
The mean historical ROE of Vaxart, Inc. over the last ten years is -81.55%. The current -110.46% ROE has changed 35.46% with respect to the historical average. Over the past ten years (40 quarters), VXRT's ROE was at its highest in in the December 2014 quarter at 7.89%. The ROE was at its lowest in in the December 2019 quarter at -49.48%.
Average
-81.55%
Median
-76.21%
Minimum
-160.23%
Maximum
32.18%
Discovering the peaks and valleys of Vaxart, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 185.97%
Maximum Annual ROE = 32.18%
Minimum Annual Increase = -597.96%
Minimum Annual ROE = -160.23%
Year | ROE | Change |
---|---|---|
2023 | -142.66% | 46.42% |
2022 | -97.43% | 159.28% |
2021 | -37.58% | 43.92% |
2020 | -26.11% | -81.86% |
2019 | -143.95% | -10.16% |
2018 | -160.23% | -597.96% |
2017 | 32.18% | -120.47% |
2017 | -157.22% | 185.97% |
2016 | -54.98% | 100.05% |
2015 | -27.48% | 117.11% |
The current ROE of Vaxart, Inc. (VXRT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-92.56%
5-year avg
-89.55%
10-year avg
-81.55%
Vaxart, Inc.’s ROE is greater than Inovio Pharmaceuticals, Inc. (-26438.24%), greater than iBio, Inc. (-126.61%), greater than Co-Diagnostics, Inc. (-54.95%), less than Novavax, Inc. (44.82%), greater than Ocugen, Inc. (-154.75%),
Company | ROE | Market cap |
---|---|---|
-26438.24% | $64.62M | |
-126.61% | $21.59M | |
-54.95% | $23.28M | |
44.82% | $1.38B | |
-154.75% | $215.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaxart, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vaxart, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Vaxart, Inc.'s ROE?
How is the ROE calculated for Vaxart, Inc. (VXRT)?
What is the highest ROE for Vaxart, Inc. (VXRT)?
What is the 3-year average ROE for Vaxart, Inc. (VXRT)?
What is the 5-year average ROE for Vaxart, Inc. (VXRT)?
How does the current ROE for Vaxart, Inc. (VXRT) compare to its historical average?